This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Eisai R&D Management Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Nathalie M. Rioux: Cancer-Therapy Patent
Introduction
Nathalie M. Rioux is an inventor associated with Woburn, Massachusetts, and Eisai R&D Management Co., Ltd. Her patent work concerns pharmaceutical approaches to cancer treatment.
Latest Patents
Rioux is listed as an inventor on 1 patent: “Method for Treating Cancer with an Oral Dosage Form of an Estrogen Receptor-Alpha Inhibitor.” The invention describes pharmaceutical compositions containing an inhibitor of human estrogen receptor alpha (ERα) and methods for using the inhibitor in cancer therapy. It focuses on dosages of H3B-6545 with defined pharmacokinetic profiles intended to support effective and safe administration to patients.
Career Highlights
Rioux’s listed patent reflects work on the development of oral cancer therapies targeting ERα. Her affiliation with Eisai R&D Management Co., Ltd. connects this work to pharmaceutical research and development.
Collaborations
Jianjun Xiao and Victoria Rimkunas are identified as Rioux’s coworkers. Their names are associated with her professional context, though the supplied information does not specify their roles in the patent.
Conclusion
Nathalie M. Rioux’s patent record highlights an invention focused on oral ERα-inhibitor dosing for cancer therapy and its intended pharmacokinetic profile.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile